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From the perspective of a patient with peripher-
al arterial occlusive disease (PAOD), the merits of a
particular treatment strategy are largely determined
by its ability to relieve current and prevent future
symptoms. New or recurrent symptoms may devel-
op in either one of the limbs. In patients with a uni-
lateral intervention it may sometimes seem as if
“latent” contralateral claudication is uncovered by
the intervention, allowing the patient to walk far
enough to elicit the new symptoms. Over time, pro-
gression of the underlying atherosclerotic process
may also lead to new contralateral symptoms.
Whereas the development of contralateral symp-
toms after a unilateral intervention is a familiar phe-
nomenon to every vascular surgeon, little seems to
be known about the exact incidence of such symp-
toms. The possibility that symptoms develop in the
other limb is, however, an essential part of the prog-
nosis of a patient and may even have implications for
the preferred treatment strategy. Estimates of the
incidence of contralateral symptoms and knowledge
of factors that predict these symptoms may therefore
help to improve clinical decision making.
The purpose of this study was (1) to determine
the incidence of contralateral symptoms, both inter-
mittent claudication and critical ischemia, in patients
with unilateral interventions for PAOD and (2) to
identify characteristics that predict these symptoms.
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Objective: The objectives of this study were (1) to determine the incidence of contralat-
eral symptoms in patients with a unilateral intervention for peripheral arterial occlusive
disease and (2) to identify characteristics that predict these symptoms.
Subjects and Setting: We included patients who had a unilateral surgical or percutaneous
intervention for peripheral arterial occlusive disease at the Brigham and Women’s
Hospital (Boston) between 1990 and 1995 (n = 532).
Main Outcome Measure: The main outcome measure was the first occurrence of con-
tralateral critical ischemia or intermittent claudication.
Results: The annual incidence rate of contralateral critical ischemia was considerable,
ranging from 3.3% to 8.3% during the first 4 years after the initial ipsilateral interven-
tion. The annual incidence rate of contralateral critical ischemia and claudication com-
bined varied from 7.7% to 21.3%. Cox regression analysis indicated that the initial ipsi-
lateral symptoms and the initial contralateral ankle/brachial index can be used to pre-
dict the occurrence of contralateral symptoms. After correction was done for these two
variables, we found no statistically significant effects for other factors including age, sex,
diabetes, smoking, antihypertensive medication, history of coronary artery disease, the
type of intervention, and the arterial level of the intervention.
Conclusions: The results of our analysis emphasize that peripheral arterial occlusive dis-
ease is essentially a two-limb problem. Especially patients with previous ipsilateral criti-
cal ischemia and patients with a poor initial contralateral ankle/brachial index have a
high risk for contralateral critical ischemia. (J Vasc Surg 1998;27:414-21.)
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METHODS
Patients. Data were obtained from the Vascular
Registry Database of the Division of Vascular Surgery
of Brigham and Women’s Hospital (Boston). This
database registers the procedures and follow-up data
of all patients with a surgical or percutaneous inter-
vention for PAOD. In this study we examined the
follow-up records of all patients who had a unilateral
intervention between April 1990 and September
1995 (n = 572). To at least reduce the possibility that
serious contralateral symptoms were already present
at the time of the initial ipsilateral procedure, we
excluded patients with a contralateral procedure
within 90 days of the ipsilateral procedure (n = 40,
7%), leaving 532 patients for the analysis.
At each follow-up visit the symptomatic status of
each limb was recorded as asymptomatic, intermit-
tent claudication, rest pain, ulcer, or gangrene. The
average duration of the follow-up was 400 days
(maximum 1714 days). We defined “contralateral
critical ischemia” as the first occurrence of rest pain,
ulcer, or gangrene in the limb that was not treated
during the initial procedure. “Contralateral symp-
toms” was defined as the first occurrence of any con-
tralateral symptoms including both critical ischemia
and intermittent claudication. In a separate analysis
we also looked at the incidence of contralateral inter-
ventions.
Data analysis. The life table method was used
to calculate the annual incidence rates and cumu-
lative risks of mortality, contralateral symptoms,
and a contralateral intervention. To examine the
effect of particular covariates on the incidence of
contralateral symptoms, a Cox regression analysis
was performed, which allows simultaneous model-
ing of multiple covariates.1 As candidate explana-
tory variables we included age, sex, the ipsilateral
symptoms before the initial intervention (intermit-
tent claudication vs critical ischemia), contralater-
al ankle/brachial index (ABI) at the time of the
Table I. Patients’ characteristics (n = 532)
Sex: female/male (%) 47/53
Age: mean; range (yr) 67; 20-93
Indication: claudication/ischemia (%) 28/72
Initial contralateral ABI: mean; SD 0.86; 0.35
Smoking (%) 37
Diabetes (%) 41
Hypertension (%) 59
History of coronary artery disease (%) 47
Fig. 1. Long-term survival of study population. Vertical bars represent standard errors of esti-
mates, and numbers represent number of patients at risk at beginning of each follow-up year.
Time: years since initial unilateral intervention.
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intervention (<0.85 vs ‡ 0.85), smoking habits,
diabetes (insulin-dependent diabetes or noninsulin-
dependent diabetes requiring oral medication),
the use of antihypertensive medication (as a mark-
er of previous hypertension), history of coronary
artery disease (angina pectoris, myocardial infarc-
tion, or coronary artery bypass graft), the arterial
level of the intervention (suprainguinal vs infrain-
guinal or combined), and the type of intervention
(bypass surgery vs percutaneous transluminal
angioplasty with or without a stent). The likeli-
hood-ratio test was used to assess the statistical
significance of the effect of covariates on the inci-
dence of contralateral symptoms ( a = 0.10).
All statistical analyses were performed with
STATA for Windows, version 4.0 (STATA
Corporation, Tex.).
RESULTS
Table I presents selected characteristics of the
patient population, and Table II presents the initial
procedures performed. The percentage of women
among this group of patients with PAOD was rela-
tively high (47%). Most of the patients were treated
for critical ischemia (72%). The prevalence of
comorbidity was high; diabetes, hypertension, and
coronary artery disease in particular were common.
In total 109 suprainguinal procedures, 403 infrain-
guinal procedures, and 20 combined suprainguinal
and infrainguinal procedures were performed. The
most common unilateral interventions performed
were femoropopliteal and femoroinfrapopliteal
bypass surgery (54% of all procedures, Table II).
Seven (1.3%) patients died within 30 days of the
intervention: four after femoropopliteal or
femoroinfrapopliteal bypass surgery, one after iliac
angioplasty, one after a combined axillofemoral and
femoroinfrapoliteal bypass procedure, and one after
a combined femorofemoral and femoropopliteal
bypass procedure. Fig. 1 shows the long-term sur-
vival of the patient population after the initial ipsi-
lateral intervention.
Overall, the incidence rate of contralateral critical
ischemia (i.e., rest pain, ulcer, or gangrene) after a
unilateral intervention decreased over time; we
found an annual incidence rate of 8.3% during the
first year, 7.9% during the second year, 5.8% during
the third year, and 3.3% during the fourth year after
the initial intervention. Among patients who had
contralateral critical ischemia, 43.5% presented with
rest pain, 43.5% with an ulcer, and 13% with gan-
grene. The annual incidence rate of contralateral
symptoms (i.e., either intermittent claudication or
critical ischemia) also demonstrated a decreasing
Table II. Initial unilateral interventions
n
Surgery
Femoropopliteal/femoroinfrapopliteal bypass 305
Femorofemoral bypass 37
Popliteo-dorsal-pedal bypass 15
Popliteotibial bypass 14
Femorofemoral + (femoropopliteal/femoroinfrapopliteal bypass) 10
Unilateral aortofemoral/iliofemoral bypass 9
Iliofemoral + (femoropopliteal/femoroinfrapopliteal bypass) 6
Femoral/popliteal endarterectomy 6
Unilateral axillofemoral bypass 2
Popliteoplantar bypass 2
Popliteotarsal bypass 2
Iliac PTA + femoroinfrapopliteal bypass 1
Profundoplasty 1
Unilateral axillofemoral bypass + femoroinfrapopliteal bypass 1
Popliteopopliteal bypass 1
Tibioplantar bypass 1
Popliteoperoneal bypass 1
Percutaneous interventions
Iliac PTA ± stent 60
Femoral/popliteal/infrapopliteal PTA 47
Femoral/popliteal thrombolysis + PTA 5
Femoral/popliteal atherectomy + PTA 2
Iliac + femoral PTA 1
Iliac thrombolysis + PTA + stent 1
Iliac PTA + stent + femoral thrombolysis 1
Femoral atherectomy 1
PTA, Percutaneous transluminal angioplasty.
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trend over time with 18.5%, 21.3%, 10.3%, and 7.7%
during the first 4 years, respectively. Among these
patients 57% presented with intermittent claudica-
tion and 43% with critical ischemia.
We found a strong association between the pre-
treatment ipsilateral symptoms and the incidence of
contralateral critical ischemia (p < 0.001). Fig. 2
plots the percentage of patients without contralater-
al ischemia as a function of time, with separate
curves for patients who initially presented with ipsi-
lateral critical ischemia and those who initially pre-
sented with ipsilateral intermittent claudication. At 2
years, for example, 20% of the patients who were ini-
tially treated for ipsilateral critical ischemia had had
critical ischemia in the contralateral limb compared
with 5% of the patients initially treated for intermit-
tent claudication. No association was demonstrated
between the incidence of any contralateral symp-
Table III. Predicted cumulative incidence of contralateral symptoms
Contralateral critical ischemia (%) Contralateral symptoms* (%)
Claudication† Ischemia‡
Time (yr) ABI ‡ 0.85 ABI <0.85 ABI ‡ 0.85 ABI <0.85 ABI ‡ 0.85 ABI <0.85
1 1.4 2.8 7.4 14.3 13.4 23.3
2 1.9 5.2 12.1 25.0 23.8 39.4
3 3.8 7.6 19.0 34.6 29.8 46.4
4 4.9 9.6 23.8 42.1 34.6 52.7
Time, Years since the initial unilateral intervention; ABI, Contralateral ankle brachial index at the time of the initial intervention.
*Contralateral intermittent claudication or critical ischemia.
†Patients initially treated for ipsilateral intermittent claudication.
‡Patients initially treated for ipsilateral critical ischemia.
Fig. 2. Percentage of patients who are free of contralateral critical ischemia. Vertical bars rep-
resent standard errors of estimates, and numbers represent number of patients at risk at begin-
ning of each follow-up year. Time: years since initial unilateral intervention. Dotted line,
patients initially treated for ipsilateral claudication (n = 150). Solid line, patients initially treat-
ed for ipsilateral critical ischemia (n = 382).
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toms and the pretreatment ipsilateral symptoms
(Fig. 3, p = 0.53). At 2 years 38% of the patients
treated for intermittent claudication and 33% of the
patients treated for critical ischemia had had symp-
toms in the contralateral limb. Among patients with
contralateral symptoms who were initially treated for
ipsilateral intermittent claudication, 95% had inter-
mittent claudication and 5% critical ischemia. In
contrast, among those with contralateral symptoms
who were initially treated for ipsilateral critical
ischemia, 33% had intermittent claudication and
67% had critical ischemia.
A Cox regression analysis was performed to
examine the effects on the incidence of contralateral
critical ischemia of multiple variables simultaneously.
A multivariate model was obtained with the pre-
treatment ipsilateral symptoms and the initial con-
tralateral ABI as explanatory variables. The regres-
sion coefficients in the model corresponded with a
fivefold increase in the incidence rate of contralater-
al critical ischemia in patients initially treated for
ipsilateral critical ischemia (incidence rate ratio: 5.4,
p < 0.001) and a twofold increase in patients with an
initial contralateral ABI <0.85 (incidence rate ratio:
2.0, p = 0.078). Adding other variables did not fur-
ther improve the model. In particular, we found no
statistically significant effect of diabetes, the type of
intervention (bypass surgery vs angioplasty), or the
arterial level (suprainguinal vs infrainguinal or com-
bined) of the intervention after adjusting for pre-
treatment ipsilateral symptoms and initial contralat-
eral ABI.
A second Cox regression analysis was performed
to examine the combined effects of variables on the
incidence of any contralateral symptoms. A simple
univariate model was obtained with the initial con-
tralateral ABI as the only explanatory variable (inci-
dence rate ratio: 1.8, p = 0.029). Adding other vari-
ables did not further improve the model.
To illustrate the results from the regression
analyses, Table III presents the predicted cumulative
percentage of patients with contralateral symptoms
for different points in time since the initial interven-
tion and for different combinations of pretreatment
symptoms and initial contralateral ABI.
We also looked at the incidence of contralateral
interventions. A total of 34 patients had a contralat-
eral intervention during the follow-up period. Fig. 4
Fig. 3. Percentage of patients who are free of any contralateral symptoms (i.e., either inter-
mittent claudication or critical ischemia). Vertical bars represent standard errors of estimates,
and numbers represent number of patients at risk at beginning of each follow-up year. Time:
years since initial unilateral intervention. Dotted line, patients initially treated for ipsilateral
claudication (n = 150). Solid line, patients initially treated for ipsilateral critical ischemia (n =
382).
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presents the life table estimates of the percentage of
our patient population without a contralateral inter-
vention for different points in time (solid line). At 2
years, for example, the cumulative incidence of con-
tralateral intervention was estimated at 13%. In this
study we excluded patients with a contralateral inter-
vention within 90 days of the initial ipsilateral inter-
vention (n = 40, see Methods). For illustration pur-
poses Fig. 4 also presents the percentage of patients
without a contralateral intervention including these
40 patients (dotted line). We found a higher inci-
dence of contralateral interventions among younger
patients, patients with diabetes, patients with a his-
tory of coronary artery disease, or patients with a
lower initial contralateral ABI. Only the effect of
diabetes, illustrated in Fig. 5, was statistically signif-
icant, however (incidence rate ratio 2.1, p = 0.04).
DISCUSSION
In this study we determined the incidence of
contralateral claudication and critical ischemia in
patients with unilateral interventions for PAOD and
developed regression models to identify factors that
predict such symptoms. The results suggest that the
incidence of contralateral symptoms is high, espe-
cially in patients with a poor contralateral ABI at the
time of the initial intervention. We also found that
patients initially treated for ipsilateral critical
ischemia had a higher risk of having contralateral
critical ischemia.
A possible limitation of our study is that the
inclusion criteria of our study did not rule out the
possibility that some patients already had contralat-
eral symptoms initially. It was not feasible to deter-
mine in retrospect whether contralateral symptoms
registered during the follow-up period were in fact
new symptoms. We did, however, exclude patients
with a contralateral intervention within 3 months of
the first intervention (7% of the original cohort).
This exclusion at least reduced the possibility that
contralateral critical ischemia or disabling claudica-
tion was present initially. A second possible limita-
tion of our study is that the inclusion of a variety of
different interventions may have introduced hetero-
geneity. For example, patients who need an infrain-
guinal bypass may have risk factors that make the
Fig. 4. Percentage of patients without contralateral intervention. Vertical bars represent stan-
dard errors of estimates, and numbers represent number of patients at risk at beginning of each
follow-up year. Time: years since initial unilateral intervention. Dotted line, including patients
with contralateral intervention <90 days (n = 572, see Methods). Solid line, excluding patients
with contralateral intervention <90 days (n = 532).
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development of contralateral ischemia more likely.
In the regression analyses we examined whether the
arterial level or the type of intervention was related
to the incidence of contralateral symptoms. We
found that after adjustment was done for pretreat-
ment ipsilateral symptoms and initial contralateral
ABI, no significant effect of these two variables was
seen. In a separate analysis we looked at the inci-
dence of contralateral symptoms among patients
with a femorofemoral bypass (n = 47). This inter-
vention is in fact not a truly unilateral procedure,
because the contralateral limb is involved in the ini-
tial procedure. Adequacy of the flow in the donor
limb was assessed before surgery with angiography.
Patients with a femorofemoral bypass and a con-
tralateral hemodynamically significant lesion as
proven by intraarterial pressure measurement had
been treated with contralateral balloon angioplasty
and were therefore excluded from this study. After
adjustment was done for pretreatment ipsilateral
symptoms and initial contralateral ABI, we did not
find a different incidence of contralateral ischemia or
claudication among patients with a femorofemoral
bypass. These findings suggest that if the previously
mentioned heterogeneity plays a role, an important
part is already captured by the regression model.
The cutoff value for the initial contralateral ABI
that we used in the analysis was the median value
(rounded off to 0.85). In secondary analyses we
used dummy variables representing the quartiles of
the distribution of the initial contralateral ABI. We
found that the risk of contralateral symptoms was
very similar for patients within the lower and upper
two quartiles, respectively. The use of alternative
cutoff values (ranging from 0.50 to 1.0) did not
improve the model.
Our study illustrates that over time many
patients treated for the symptoms of one limb return
with symptoms of the contralateral limb. In some of
the patients contralateral symptoms may have been
latently present from the start, being obscured by
the more serious symptoms of the index limb and
becoming only apparent as mobility increased as a
result of the intervention. During the follow-up,
however, this effect may have been moderated by an
opposite trend, because patients tend to lead more
sedentary lives as they get older. Development of
contralateral symptoms may also reflect progression
Fig. 5. Percentage of patients without contralateral intervention, effect of diabetes. Vertical
bars represent standard errors of estimates, and numbers represent number of patients at risk
at beginning of each follow-up year. Time: years since initial unilateral intervention. Dotted
line, patients without diabetes (n = 312). Solid line, patients with diabetes (n = 219).
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of the underlying atherosclerotic process. Ricco,2 for
example, reported that after an average follow-up of
22 months, a stenosis had developed in 5% of previ-
ously normal iliac arteries. Walsh et al.3 found dis-
ease progression in 12 of 45 superficial femoral
arteries after an average follow-up of 37 months and
reported an average progression rate of 4.5% per
year.
We are not aware of any previous study that
specifically reports the incidence of contralateral
symptoms after unilateral vascular procedures. A few
studies, however, have looked at the rates of con-
tralateral revascularization after unilateral proce-
dures.4-7 Tarry et al.,7 for example, reported a
cumulative incidence of 13% at 2 years and 30% at 5
years, which closely agrees with our findings. They
also reported that younger age, diabetes, history of
coronary artery disease, and lower initial contralater-
al ABI predicted higher incidence of contralateral
interventions. We found the same trends in our pop-
ulation, but only the effect of diabetes was statisti-
cally significant. Tarry et al. suggested that estimates
of the probability of a future contralateral interven-
tion might be helpful in deciding whether to use or
spare the contralateral saphenous vein at the initial
intervention. We believe, however, that this issue
may not be as important as it used to be, because
currently many alternative treatment options are
available, for example, infrainguinal angioplasty in
selected patients.
It is difficult to understand the association
between pretreatment ipsilateral critical ischemia
and the incidence of contralateral critical ischemia
as a causal relation. At least part of the effect may
probably be explained as the combined effect of
underlying systemic risk factors that increase the
overall risk of critical ischemia, and previous ipsilat-
eral critical ischemia may then be interpreted as sim-
ply an indicator of a poor risk factor status. We
found, for example, a small univariate effect for dia-
betes (odds ratio 1.7) that disappeared when “pre-
treatment ipsilateral symptoms” was added as an
explanatory variable.
The possibility that contralateral symptoms may
appear is not only an essential part of the prognosis
after a unilateral intervention, it may also have impli-
cations for clinical and health policy decision mak-
ing. In the past few years several decision models
have been developed that study the cost-effectiveness
of alternative treatment strategies in patients with
PAOD.8-10 All of these models assume that symp-
toms are and will be limited to one limb. Violation
of this assumption could result in a bias against
strategies that treat two limbs simultaneously such as
exercise therapy and the implantation of aortic bifur-
cation grafts. The results of our study suggest that it
may be essential to incorporate the possibility of
contralateral symptoms in a comparative analysis of
treatment alternatives.
The results of our study emphasize that PAOD is
essentially a two-limb problem. Especially patients
treated initially for previous ipsilateral critical
ischemia and those with a poor initial contralateral
ABI have a high risk for contralateral critical
ischemia.
We thank Ms. Julie Lombara for her assistance in
obtaining the Vascular Registry data.
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